SAN FRANCISCO, Oct. 10, 2018 /PRNewswire-PRWeb/ -- uBiome, the leader in microbial genomics, has launched a research study to examine the potential connection between weight and gut health. The study is in collaboration with PlateJoy, a company that provides personalized meal plans and recipes tailored to its users' needs, goals, and lifestyles. Qualified study participants will partake in PlateJoy's 16-week coaching program and test their gut microbiome with uBiome's clinical SmartGut™ test.
"Advancing microbiome research part of uBiome's mission, and it is especially exciting to explore clinical implications when investigating aspects of human health," said Dr. Jessica Richman, PhD, co-founder and CEO of uBiome. "We are thrilled to partner with PlateJoy to conduct this study and collectively gain insights on weight loss and the gut microbiome."
About this study collaboration, PlateJoy CEO Christina Bognet said, "Unlocking the secrets of the microbiome will be part of this century's most impactful contribution to medicine. We now know that the bacteria in our gut dictate much of human health, but most studies are done in animal models or in a petri dish. This partnership will allow real people to get a sense of how their own microbiomes are changing in response to adopting healthier lifestyles, a positive feedback loop that will not only contribute to scientific discovery but hopefully to better outcomes as well."
SmartGut, which must be prescribed by a healthcare provider, uses precision sequencing™ technology to identify microbes in a patient's gut that might be affecting his or her weight or gut or metabolic conditions. SmartGut helps doctors better understand common conditions related to the gut, such as bloating, constipation, diarrhea and other symptoms of irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease.
SmartGut samples are processed in uBiome's CLIA-licensed and CAP-accredited laboratory in San Francisco, California. The College of American Pathologists, with more than 18,000 members, is the world's leading organization of board-certified pathologists. Its goal is to serve patients, physicians, and the public by encouraging, promoting, and supporting excellence in pathology and laboratory medicine.
Visit platejoy.com/ubiome to request to participate in this study. For more information on SmartGut and how to request a kit, please visit uBiome's study page.
About uBiome Founded in 2012, uBiome is the leader in microbial genomics. The Company's mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets.
uBiome's commercial products include SmartGut™, the world's first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn's Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women's health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome's platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company's Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit uBiome.com.
SOURCE Ubiome
Advertisement
"Advancing microbiome research part of uBiome's mission, and it is especially exciting to explore clinical implications when investigating aspects of human health," said Dr. Jessica Richman, PhD, co-founder and CEO of uBiome. "We are thrilled to partner with PlateJoy to conduct this study and collectively gain insights on weight loss and the gut microbiome."
Advertisement
About this study collaboration, PlateJoy CEO Christina Bognet said, "Unlocking the secrets of the microbiome will be part of this century's most impactful contribution to medicine. We now know that the bacteria in our gut dictate much of human health, but most studies are done in animal models or in a petri dish. This partnership will allow real people to get a sense of how their own microbiomes are changing in response to adopting healthier lifestyles, a positive feedback loop that will not only contribute to scientific discovery but hopefully to better outcomes as well."
SmartGut, which must be prescribed by a healthcare provider, uses precision sequencing™ technology to identify microbes in a patient's gut that might be affecting his or her weight or gut or metabolic conditions. SmartGut helps doctors better understand common conditions related to the gut, such as bloating, constipation, diarrhea and other symptoms of irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease.
SmartGut samples are processed in uBiome's CLIA-licensed and CAP-accredited laboratory in San Francisco, California. The College of American Pathologists, with more than 18,000 members, is the world's leading organization of board-certified pathologists. Its goal is to serve patients, physicians, and the public by encouraging, promoting, and supporting excellence in pathology and laboratory medicine.
Visit platejoy.com/ubiome to request to participate in this study. For more information on SmartGut and how to request a kit, please visit uBiome's study page.
About uBiome Founded in 2012, uBiome is the leader in microbial genomics. The Company's mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets.
uBiome's commercial products include SmartGut™, the world's first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn's Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women's health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome's platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company's Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit uBiome.com.
SOURCE Ubiome
